117 related articles for article (PubMed ID: 22236202)
1. Thymidine kinase assay in canine lymphoma.
Elliott JW; Cripps P; Blackwood L
Vet Comp Oncol; 2013 Mar; 11(1):1-13. PubMed ID: 22236202
[TBL] [Abstract][Full Text] [Related]
2. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
3. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma.
Sharif H; von Euler H; Westberg S; He E; Wang L; Eriksson S
Vet J; 2012 Oct; 194(1):40-7. PubMed ID: 22516918
[TBL] [Abstract][Full Text] [Related]
4. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay.
Von Euler HP; Rivera P; Aronsson AC; Bengtsson C; Hansson LO; Eriksson SK
Int J Oncol; 2009 Feb; 34(2):505-10. PubMed ID: 19148486
[TBL] [Abstract][Full Text] [Related]
5. Plasma thymidine kinase activity in dogs with lymphoma and leukemia.
Nakamura N; Momoi Y; Watari T; Yoshino T; Tsujimoto H; Hasegawa A
J Vet Med Sci; 1997 Oct; 59(10):957-60. PubMed ID: 9362053
[TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease.
von Euler H; Einarsson R; Olsson U; Lagerstedt AS; Eriksson S
J Vet Intern Med; 2004; 18(5):696-702. PubMed ID: 15515587
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*.
Thamm DH; Kamstock DA; Sharp CR; Johnson SI; Mazzaferro E; Herold LV; Barnes SM; Winkler K; Selting KA
Vet Comp Oncol; 2012 Dec; 10(4):292-302. PubMed ID: 22236280
[TBL] [Abstract][Full Text] [Related]
8. A method to distinguish between the de novo induction of thymidine kinase mutants and the selection of pre-existing thymidine kinase mutants in the mouse lymphoma assay.
Wang J; Heflich RH; Moore MM
Mutat Res; 2007 Jan; 626(1-2):185-90. PubMed ID: 17055776
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs.
Wolfesberger B; Tonar Z; Fuchs-Baumgartinger A; Walter I; Skalicky M; Witter K; Thalhammer JG; Pagitz M; Kleiter M
Res Vet Sci; 2012 Jun; 92(3):444-50. PubMed ID: 21596405
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma.
Marconato L; Crispino G; Finotello R; Mazzotti S; Zini E
J Am Vet Med Assoc; 2010 May; 236(9):969-74. PubMed ID: 20433396
[TBL] [Abstract][Full Text] [Related]
11. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
[TBL] [Abstract][Full Text] [Related]
12. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.
Madewell BR
J Vet Intern Med; 2004; 18(5):595-6. PubMed ID: 15515571
[TBL] [Abstract][Full Text] [Related]
13. Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression.
Wolfesberger B; Tonar Z; Witter K; Guija de Arespacohaga A; Skalicky M; Walter I; Thalhammer JG; Egger GF
Res Vet Sci; 2008 Aug; 85(1):56-61. PubMed ID: 17888471
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
15. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma.
Jeglum KA; Young KM; Barnsley K; Whereat A; McGrath D; Hutson C
J Biol Response Mod; 1986 Apr; 5(2):168-75. PubMed ID: 3734843
[TBL] [Abstract][Full Text] [Related]
16. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
[TBL] [Abstract][Full Text] [Related]
17. Expression of the high mobility group A1 (HMGA1) and A2 (HMGA2) genes in canine lymphoma: analysis of 23 cases and comparison to control cases.
Joetzke AE; Sterenczak KA; Eberle N; Wagner S; Soller JT; Nolte I; Bullerdiek J; Murua Escobar H; Simon D
Vet Comp Oncol; 2010 Jun; 8(2):87-95. PubMed ID: 20579321
[TBL] [Abstract][Full Text] [Related]
18. Serum thymidine kinase activity in clinically healthy and diseased cats: a potential biomarker for lymphoma.
Taylor SS; Dodkin S; Papasouliotis K; Evans H; Graham PA; Belshaw Z; Westberg S; von Euler HP
J Feline Med Surg; 2013 Feb; 15(2):142-7. PubMed ID: 23076596
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy.
Meyer A; Eberle N; Bullerdiek J; Nolte I; Simon D
Vet Comp Oncol; 2010 Jun; 8(2):127-37. PubMed ID: 20579326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
